On June 5, 2023, immediately following the closing of the Private Placement, the Board of Directors of Telesis Bio, Inc. was increased from seven to eight directors and Paul Meister, a partner at Novalis LifeSciences LLC, was appointed as a director of the Company to fill the resulting vacancy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.51 USD | +0.22% | +8.67% | -37.20% |
May. 09 | Earnings Flash (TBIO) TELESIS BIO Reports Q1 Revenue $3.4M | MT |
May. 09 | Telesis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.20% | 7.54M | |
+11.91% | 227B | |
+15.46% | 198B | |
+18.58% | 142B | |
+30.36% | 111B | |
+0.38% | 64.16B | |
+17.74% | 54.1B | |
+5.82% | 51.41B | |
+11.23% | 45.32B | |
+5.73% | 37.32B |
- Stock Market
- Equities
- TBIO Stock
- News Telesis Bio, Inc.
- Telesis Bio, Inc. Appoints Paul Meister as Director